Champions Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2023
March 15, 2023 at 04:00 pm EDT
Share
Champions Oncology, Inc. reported earnings results for the third quarter and nine months ended January 31, 2023. For the third quarter, the company reported net loss was USD 2.44 million compared to net income of USD 0.787 million a year ago. Basic loss per share from continuing operations was USD 0.18 compared to basic earnings per share from continuing operations of USD 0.06 a year ago. Diluted loss per share from continuing operations was USD 0.18 compared to diluted earnings per share from continuing operations of USD 0.05 a year ago.
For the nine months, net loss was USD 2.77 million compared to net income of USD 0.892 million a year ago. Basic loss per share from continuing operations was USD 0.2 compared to basic earnings per share from continuing operations of USD 0.07 a year ago. Diluted loss per share from continuing operations was USD 0.2 compared to diluted earnings per share from continuing operations of USD 0.06 a year ago.
Champions Oncology, Inc. is a technology-enabled research organization engaged in creating transformative technology solutions to be utilized in drug discovery and development. The Company's research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. The Companyâs TumorGraft Technology Platform (The Platform) provides select services to pharmaceutical and biotechnology companies. Its software as-a-service business is centered around its software platform and data tool, Lumin Bioinformatics (Lumin), which contains comprehensive information derived from its research services and clinical studies. Its drug discovery and development business leverage the computational and experimental capabilities within its platforms. Its discovery strategy utilizes its datacenter, coupled with artificial intelligence and other advanced computational analytics, to identify therapeutic targets.
CHAMPIONS ONCOLOGY, INC. 
